FDA and EMA approve Novartis’ treatment for follicular lymphoma patients

The FDA and EMA have accepted Novartis’ Supplemental Biologics License Application (sBLA) and Type II Variation for Kymriah? in patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two prior lines of treatment. 

read more